11月17日,资本邦了解到,美股上市公司尚高生命科学(代码:SISI.US)发布2022财年一季报。2021年7月1日-2021年9月30日,公司营业收入62.98万美元,同比下降37.52%,归属母公司净亏损1423.83万美元,亏损同比扩大1246.40%,基本每股收益为-1.71美元。公司所属行业为制药。其中,罗布麻产品收入1.35万美元,其他农产品收入61.62万美元。公司报告期内,期末...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.